Xofigo (Radium-223) Approved for Prostate Cancer With Bone Mets

May 16, 2013

A novel radiopharmaceutical agent has been approved by the US Food and Drug Administration (FDA) for use in the treatment of prostate cancer.

The product, radium-223 dichloride (formerly known as alpharadin), will be marketed as Xofigo by Algeta and Bayer for use in men with symptomatic metastatic castration-resistant prostate cancer that has spread to the bone but not to other organs. It is intended for men whose cancer has spread after medical or surgical therapy to lower testosterone, according to the FDA.